398 related articles for article (PubMed ID: 20191332)
1. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M; Tefferi A
Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
[TBL] [Abstract][Full Text] [Related]
2. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Tefferi A; Skoda R; Vardiman JW
Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
[TBL] [Abstract][Full Text] [Related]
4. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
5. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
7. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
8. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
9. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
10. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
[TBL] [Abstract][Full Text] [Related]
11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
12. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of JAK2-positive myeloproliferative neoplasms.
Kiladjian JJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
18. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J; Hyjek E
Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
[TBL] [Abstract][Full Text] [Related]
19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
20. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
